My watch list  

DeveloGen AG receives US$ 500.000 Funding from the Juvenile Diabetes Research Foundation for Beta Cell Research


DeveloGen AG announced that it will receive US$ 500,000 from the Juvenile Diabetes Research Foundation, New York, USA (JDRF). The funds are dedicated to aide in the research of mechanisms for the protection of beta cells.

In this two year project titled "Development of Novel Therapeutic Agents Enhancing Human Beta Cell Survival", DeveloGen, together with the Istituto San Raffaele, Milan, Italy, will investigate the influence of certain substances on human beta cells. A particular focus of the work will be on mechanisms which have the potential to protect insulin producing beta cells from dying. The research project is expected to deliver important insight into the development of novel therapies with the potential of a disease modifying treatment of diabetes mellitus.

Dr. Cord Dohrmann, CEO of DeveloGen AG said: "The development of novel therapies in the area of beta cell regeneration and beta cell protection belongs to DeveloGen's core interests. We are delighted and proud to perform this project together with the Istituto San Raffaele. The repeated receipt of funding from the JDRF, the world's most renowned privately funded charitable organisation in the area of diabetes, is appreciation of the work done at DeveloGen and motivation at the same time".

Richard A. Insel, MD, Chief Scientific Officer at JDRF, said: "JDRF is pleased to be supporting research to pursue new approaches to promote the functioning and survival of insulin-producing beta cells. The results of this project could contribute to the discovery of break-through therapies for people with type 1 diabetes."

Facts, background information, dossiers
More about DeveloGen
  • News

    Evotec announces metabolic disease alliance with MedImmune

    Evotec AG announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca), in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells. The li ... more

    Evotec Completes Acquisition of DeveloGen

    Following the successful fulfilment of various Closing conditions, the sellers of 99.3% of the shares in DeveloGen AG transferred their shares to Evotec AG. Evotec AG issues 6,750,014 new Evotec Shares from its authorized capital as part consideration for the transaction. Following the re ... more

    DeveloGen Reports Positive Phase 1 Clinical Trial Results for DG3173

    DeveloGen AG reported positive results from a Phase 1 study for DG3173, a novel somatostatin analogue. The results of the study indicate that DG3173 has an excellent safety and tolerability profile at all doses administered. The Phase 1 trial was designed as a randomized, double-blind, pla ... more

More about Juvenile Diabetes Research Foundation
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE